Clinical review pending. This article has not yet been reviewed by a licensed clinician, and we would rather say so than print a name that does not exist.
This is general regulatory context for practices. It is not legal or clinical advice, and it names no product.
A practice that offers a prepared medicine through a 503A pharmacy is taking part in a process with clear roles. Knowing the order of the steps, and who owns each one, makes the service easier to explain and easier to document.
Step one: a prescriber's decision for one patient
Everything starts with a licensed prescriber and a named patient. FDA describes this kind of preparation as making a medication tailored to the needs of an individual patient. FDA also says it should only be used for patients whose medical needs cannot be met by an approved drug, and gives examples such as a patient with an allergy to a dye, or a child who cannot swallow a tablet and needs a liquid form.
That judgment belongs to the prescriber. It should be written down in the patient's record, along with why an approved product does not meet this patient's need.
Step two: a patient-specific prescription
Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions under which this kind of medicine is exempt from FDA approval before marketing. FDA names one of those conditions directly: the medicine must be prepared based on the receipt of a valid patient-specific prescription.
In practice that means:
- One prescription, one named patient. A 503A order is not a way to keep general office stock.
- The prescriber signs for that patient. Staff can prepare paperwork, but the decision is the prescriber's.
Outsourcing facilities registered under section 503B are a separate category. FDA explains that they may also fill orders that are not for an identified individual patient, such as office stock, and that they follow current good manufacturing practice. Our earlier guide, how the 503A and 503B pathways work, covers that difference.
Step three: preparation by a licensed pharmacist
Under federal law, this preparation is done by a licensed pharmacist in a state-licensed pharmacy or a federal facility, or by a physician. FDA notes that state boards of pharmacy generally have primary responsibility for day-to-day oversight of these pharmacies, and that FDA also conducts surveillance and for-cause inspections.
FDA is also clear that current good manufacturing practice requirements do not apply to medicines prepared under section 503A. Other federal law still applies in every setting, including the rules against insanitary conditions.
Step four: the label
Section 503A also exempts these medicines from the federal requirement for labeling with adequate directions for use. That makes the label and the conversation around it more important, not less. Your state's pharmacy rules set what the pharmacy label must show. The practice should make sure the patient knows:
- whether the medicine is approved or compounded,
- that a compounded medicine is not FDA-approved, and that FDA has not reviewed it for safety, effectiveness, or quality before it is marketed,
- who to call with questions.
Step five: after the patient has the medicine
The prescriber stays the patient's point of contact. FDA encourages anyone who has an adverse reaction to a medicine, including a compounded one, to tell their health care professional and to report it directly to FDA. A practice should have a simple, written way to take those calls and file those reports.
Where SiriusRx fits
Sirius Peptides, by SiriusRx, gives practices a workspace and managed ordering. SiriusRx works with practices. It does not sell to patients and it does not provide medical care. The prescriber decides every order, for a named patient.
References
- U.S. Food and Drug Administration. "Human Drug Compounding Laws."
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers."
- U.S. Food and Drug Administration. "Human Drug Compounding."
- U.S. Food and Drug Administration. "Consumer and Health Care Professional Information."
These are public, peer reviewed sources about the underlying physiology. They are not studies of SiriusRx and they do not describe results anyone should expect from us.

